CAMBRIDGE, Mass.--(BUSINESS WIRE)--Garuda Therapeutics, a company developing off-the-shelf, durable blood stem cell therapies, today announced that Dhvanit Shah, Ph.D., Co-Founder, President and Chief Executive Officer, will present virtually at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022 (Tuesday) at 5:30 pm EST.
Garuda’s platform for generating off-the-shelf, self-renewing blood stem cells is designed to provide patients with rapid and broad access to consistent, durable, HLA-matched, transgene-free blood stem cell therapies. Currently, patients seeking a blood stem cell transplant must find a suitable human donor as a source of blood stem cells. Racial minority patients face greater barriers than white patients in finding suitable blood stem cell matches. Like bone marrow transplants, Garuda’s technology has the potential to address, and possibly cure, more than 70 diseases. It also overcomes many limitations of current practices and could potentially offer treatment options to patients irrespective of their racial background.
Garuda Therapeutics was founded by Dhvanit Shah, Ph.D., David Scadden, M.D., and Sean Morrison, Ph.D., who are industry and academic leaders with a strong history of developing transformative medicines and successful company exits. The company completed a Series A financing of $72 million led by Aisling Capital, Northpond Ventures and Orbimed, supported by Cormorant Asset Management, Ridgeback Capital Investments, Monashee Investment Management, Sectoral Asset Management, National Resilience, Inc. (Resilience), Mass General Brigham Ventures, among others. Garuda has also attracted veterans like Eric Aguiar, M.D., of Aisling; Carl Gordon, Ph.D., CFA, of OrbiMed; Shaan C. Gandhi, M.D., D.Phil, of Northpond; Rahul Singhvi, Sc.D., of Resilience; and Laurence Reid, Ph.D., of Decibel Therapeutics to its board of directors.
About Garuda Therapeutics
Garuda Therapeutics seeks to create a world that eliminates the dependency on donor or patient cells for blood stem cell transplants. Our platform technology for generating off-the-shelf, self-renewing blood stem cells is poised to provide patients with rapid and broad access to consistent, durable, HLA-compatible and transgene-free blood stem cell therapies. Like bone marrow transplants, our technology could provide potentially curative therapies for more than 70 diseases. https://garudatx.com/
